Accueil>>Signaling Pathways>> MAPK Signaling>> RSK>>BIX 02565

BIX 02565

Catalog No.GC12982

BIX 02565 est un puissant inhibiteur de la ribosome S6 kinase 2 (RSK2) avec une IC50 de 1,1 nM.

Products are for research use only. Not for human use. We do not sell to patients.

BIX 02565 Chemical Structure

Cas No.: 1311367-27-7

Taille Prix Stock Qté
10mM (in 1mL DMSO)
163,00 $US
En stock
2mg
87,00 $US
En stock
5mg
162,00 $US
En stock
10mg
252,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of BIX 02565

BIX 02565 is a novel inhibitor of ribosomal S6 kinase 2 with IC50 value of 1 nM [1].

Ribosomal S6 kinase (RSK) is a Na/H exchanger (NHE) -activating factor and is important for pH maintenance during the early phase of cellular stress. While, NHE activation leads to Ca2+ overload and cardiac hypertrophy over longer periods [2].

BIX 02565 is a novel RSK2 inhibitor. Also, BIX 02565 inhibited adrenergic ɑ1A-, ɑ1B-, ɑ1D-, ɑ2A-, β2- and imidazoline I2 receptors with IC50 values ranging from 0.052 to 1.820 μM. These receptors played important roles in the regulation of vascular tone and cardiac function [2]. Also, BIX 02565 inhibited LRRK2 and PRKD1 with IC50 values of 16 and 35 nM [1].

In the rat CV screen, BIX 02565 (1, 3 and 10 mg/kg) significantly decreased heart rate (-93 +13 beats/min) and mean arterial pressure (MAP: to -65 +6 mm Hg below baseline). In telemetry-instrumented rats, BIX 02565 (30, 100 and 300 mg/kg for 4 days) reduced MAP (to -39 + 4 mm Hg) in a concentration-dependent way [2].

References:
[1].  Kirrane TM, Boyer SJ, Burke J, et al. Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity. Bioorg Med Chem Lett, 2012, 22(1): 738-742.
[2].  Fryer RM, Muthukumarana A, Chen RR, et al. Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors. J Pharmacol Exp Ther, 2012, 340(3): 492-500.

Protocol of BIX 02565

Kinase experiment [1]:

Determination of IC50 at RSK2

Compounds were assessed for their ability to inhibit the phosphorylation of a substrate peptide by RSK2 as described previously (Boyer et al., 2011). In brief, human RSK2 protein (Invitrogen, Carlsbad, CA) was used to measure kinase activity utilizing Kinase GloPlus (Promega, Madison, WI) that uses a luciferin-luciferase based detection reagent to quantify residual ATP. The relative light unit signal was measured on an LJL Analyst (Molecular Devices, Sunnyvale, CA) in luminescence mode using 384 aperture; relative light unit signals were converted to percentage of control; the IC50 was fitted to a standard four-parameter logistic equation.

Animal experiment [1]:

Animal models

Rats model

Dosage form

1, 3, 10, 30, 100, and 300 mg/kg, p.o. once per day for 4 days

Applications

BIX 02565 (1, 3, and 10 mg/kg) elicited decreases in both mean arterial pressure and heart rate in anesthetized rats. Moreover, BIX 02565 (30, 100, and 300 mg/kg) also induced concentration-dependent decreases in mean arterial pressure (MAP) after each daily oral dose in telemetry-instrumented conscious rats.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Fryer, R. M., Muthukumarana, A., Chen, R. R., Smith, J. D., Mazurek, S. N., Harrington, K. E., Dinallo, R. M., Burke, J., DiCapua, F. M., Guo, X., Kirrane, T. M., Snow, R. J., Zhang, Y., Soleymanzadeh, F., Madwed, J. B., Kashem, M. A., Kugler, S. Z., O'Neill, M. M., Harrison, P. C., Reinhart, G. A. and Boyer, S. J. (2012) Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors. J Pharmacol Exp Ther. 340, 492-500

Chemical Properties of BIX 02565

Cas No. 1311367-27-7 SDF
Canonical SMILES C[C@](N12)([H])CCNC(C2=CC3=C1C=C(/C(O)=N/C4=NC5=CC=CC=C5N4CCCN(C)C)C=C3)=O
Formula C26H30N6O2 M.Wt 458.56
Solubility ≥ 22.95mg/mL in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of BIX 02565

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.1807 mL 10.9037 mL 21.8074 mL
5 mM 0.4361 mL 2.1807 mL 4.3615 mL
10 mM 0.2181 mL 1.0904 mL 2.1807 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of BIX 02565

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

Avis

Review for BIX 02565

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BIX 02565

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.